Program
CID-103
Its studies are mostly in Purpura · Multiple Myeloma, led by CASI Pharmaceuticals.
Furthest: phase 2, since Jun 4, 20253 company-led studies, 2 open or runningNext primary completion: May 2030 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CASI Pharmaceuticals | 32 open or running | phase 2since Jun 4, 2025 | Feb 8, 2021 | May 2030phase 2 · NCT07641426 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 8, 2021First study: phase 1 study in Multiple MyelomaFirst studyNCT04758767 · 10 enrolled · France, United Kingdom
- Jun 4, 2025Phase 2 study in PurpuraNCT07017725 · 75 planned · China
- May 20, 2026Phase 2 study in Antibody Mediated RejectionNCT07641426 · 58 planned · China
Ahead
- May 2030Primary completion: phase 2 study in Antibody Mediated RejectionNCT07641426
TargetBeta
CD38 →read by rule
“A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38), ”NCIt, by rule
Other programs on CD38
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daratumumabrule | Johnson & Johnson | phase 4 | 44 |
| isatuximabrule | Sanofi | phase 3 | 23 |
| felzartamabrule | Biogen | phase 3 | 15 |
| mezagitamabrule | Takeda | phase 3 | 11 |
| lumrotatugrule | Keymed Biosciences | phase 3 | 10 |
| Anti-CD38 Monoclonal Antibody SCTC21Crule | Sinocelltech Group | phase 3 | 5 |
| sanritatugrule | Hangzhou Sumgen Biotech | phase 3 | 5 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD38 Monoclonal Antibodyrule | Chongqing Genrix Biopharmaceutical | phase 2 | 1 |
| Anti-CD38 Antibody-drug Conjugate ABBV-438 | AbbVie | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07641426Antibody Mediated Rejection · China | 2 | Recruiting | May 2030 | 58 |
| NCT07017725Purpura · China | 2 | Recruiting | Jun 1, 2026 | 75 |
| NCT04758767Multiple Myeloma · France, United Kingdom | 1 | Completed | Jan 19, 2023 | 10 |
How it is read
Names in the registry
- “CID-103”, 3 entries
Conditions, from the studies’ own filings
- Purpura, 1 study
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.